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Abstract
The occurrence of catechol-O-methyltransferase (COMT) in presynaptic neurons remains controversial. This study utilized
dopaminergic and noradrenergic toxins to assess the presence of COMT in the presynaptic neurons originating from the
substantia nigra, ventral tegmental area or locus coeruleus. Destruction of dopaminergic and noradrenergic neurons was
assessed by measuring the dopamine and noradrenaline content in the projection areas of these neurons. Additionally,
COMT protein expression and activity were examined in several projection areas to determine whether there are any
changes in COMT values. Colocalization studies were done to identify COMT-containing postsynaptic neurons. Despite
successful lesioning of dopaminergic and noradrenergic neurons, no changes in COMT protein expression or activity could
be noted. These results strongly suggest that COMT is not present in presynaptic dopaminergic and noradrenergic neurons.
There was a high colocalization of COMT with the GABAergic marker of short neurons both in the striatum and cortex but
only a weak, if any, with the cholinergic marker in the cortex.
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Introduction
In mammals, catechol-O-methyltransferase (COMT) O-
methylates catechol containing compounds, like catecholamines,
L-dopa, catecholestrogens and dietary polyphenols [1]. COMT
is widely distributed throughout the body with highest activities
observed in peripheral tissues, particularly in the liver, kidney
and gut [1]. The localization of COMT in the brain still
remains controversial. COMT is an intracellular enzyme that
exists in two isoforms: a membrane-bound (MB-COMT) and
a soluble form (S-COMT). Neither of the two isoforms is
present in the extracellular fluid nor the plasma membrane [1].
S-COMT resides in the cytoplasm and nuclei while MB-COMT
is associated with the rough endoplasmic reticulum [1]. Along
with immunohistochemical studies, a number of lesion studies
concluded that COMT does not reside in presynaptic dopami-
nergic neurons and is present only at low levels in postsynaptic
neurons [2;3;4]. Instead, high levels of COMT protein were
found in non-neuronal cells, i.e. in ependymal cells of the
cerebral ventricles, choroid plexus and glial cells [3;5;6;7].
Interestingly, a recent study by Matsumoto and colleagues [8]
detected higher COMT mRNA levels in neurons than in non-
neuronal cells in the prefrontal cortex and striatum, in both
human and rats. However, COMT mRNA levels have pre-
viously been shown to poorly correlate with actual COMT
protein levels [9]. In contrast to previous reports, Chen and
colleagues [10] recently proposed that MB-COMT is present in
presynaptic neurons and that its catalytic domain is oriented
towards the extracellular space in a primary culture of rat
cortical neurons.
This study investigated the localization of COMT protein in
dopaminergic and noradrenergic terminals of the rat brain.
Selective lesions of dopaminergic cell bodies were made by
injecting 6-hydroxydopamine (6-OHDA) site-specifically to the
lateral substantia nigra (SN) or ventral tegmental area (VTA).
Noradrenergic neurons originating from the locus coeruleus were
damaged by intraperitoneal (i.p.) injection of N-(2-chloroethyl)-N-
bromobenzylamine hydrochloride (DSP-4) [11]. COMT protein
expression and enzyme activity were measured in the intact and
lesioned projection areas to assess the presence of COMT in the
distinct presynaptic dopaminergic and noradrenergic sites. More-
over, colocalization of COMT with GABAergic and cholinergic
neuronal markers were studied using double-label immunofluo-
rescence.
Materials and Methods
Chemicals
All chemicals used were purchased from Sigma-Aldrich (St.
Louis, MO, USA) unless an alternative source is specified in the
text. Ethanol was purchased from Altia (Helsinki, Finland).
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Figure 1. Illustration of the injection sites in dopaminergic lesions in the rat brain. (A) Anatomical locations of the two injection sites in the
Paxinos Rat Atlas (circles). (B) Actual tissue slice demonstrating the positions of the two injection sites (blue colour). (C) Illustration of the main
projection areas of the ventral tegmental area (VTA) and lateral substantia nigra (SN). (D) Projection areas of the locus coeruleus.
doi:10.1371/journal.pone.0061392.g001
Table 1. Details of primary antibodies.
Antigen COMT
Glutamic acid decarboxylase
65/67 (GAD 65/67)
Choline acetyltransferase
(ChAT) Tyrosine-hydroxylase (TH)
Marker for COMT protein GABAergic cells Cholinergic cells Dopaminergic cells
Species Mouse IgG monoclonal Rabbit IgG Rabbit IgG Rabbit IgG
Immunogen Mouse COMT aa. 26–141 Synthetic peptide. Sequence: K-
DIDFLIEEIERLGQDL
Synthetic peptide from porcine
ChAT. Sequence: H-
GLFSSYRLPGHT- QDTLVAQKSS-NH2
Denaturated tyrosine
hydroxylase from rat
Manufacturer BD Biosciences; San Diego,
CA, USA
Millipore; Billerica, MA, USA Millipore Millipore
Product # Product 611970 Product AB1511 Product AB5042 Product AB152
Dilution used 1:400 1:500 1:500 1:500
Specificity reference Western blot [7] Western blot; Manucfacturer’s
datasheet
Preadsorption control, Western
blot [32]
Western blot; Manufacturer’s
datasheet
doi:10.1371/journal.pone.0061392.t001
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Ethics Statement
Male adult Wistar rats (body weights between 265–360 g in 6-
OHDA studies and 210–240 g in DSP-4 studies) were obtained
from Harlan, The Netherlands. Rats were housed in clear
polycarbonate cages in groups of 2–4. All rats were maintained
under a 12:12 h light/dark cycle with lights on from 06:00 to
18:00 at an ambient temperature of 20–22uC. Standard rat chow
and tap water were available ad libitum. The experiments were
conducted according to the ‘‘European Convention for the
protection of Vertebrate Animals used for Experimental and
other Scientific purposes’’, and reviewed and approved by the
National Animal Experiment Board.
Treatment Groups
Rats were divided into 3 groups: group 1 received unilateral
infusions of 6-OHDA to the lateral SN (n= 15), group 2 received
unilateral infusions of 6-OHDA to the VTA (n= 15) and group 3
received i.p. injections of DSP-4 (n= 20) or saline (n = 20). To
prevent noradrenergic neurons from taking up 6-OHDA, rats
received i.p. injections of desipramine (25 mg/kg) 30 min prior to
infusion of 6-OHDA. Desipramine effectively protects noradren-
ergic neurons in 6-OHDA treated rats [12]. As we only infused 6-
OHDA unilaterally, the intact side of the brain was used as
a control value to decrease the number of experimental animals.
In earlier studies we have not seen any differences when using
either the intact side or the intact sham-operated controls. Animals
were sacrificed 3 weeks (6-OHDA groups) or 2 weeks (DSP groups)
post lesion and COMT protein expression and activity were
measured from respective projection areas of the lateral SN, VTA
or locus coeruleus.
6-OHDA Lesions of the Lateral SN
Stereotaxic surgery and injections of 6-OHDA were performed
in four sessions under isoflurane anaesthesia (4.5% during
induction and 2–3% during maintenance). A total amount of
8 mg of 6-OHDA (4 mg/ml, dissolved in 0.02% ascorbic acid) was
unilaterally injected into the right lateral SN (A/P 25.3; L/M
23.0; D/V 26.6) at a flow rate of 0.5 ml/min using a 10 ml
Hamilton microsyringe run by a microdialysis pump (QSI,
Stoetling, Wood Dale, Il, USA). The coordinates were measured
from bregma according to the rat brain atlas [13]. For an
illustration of the injection site and main projection ares
[14;15;16], please refer to Figure 1A–C.
6-OHDA Lesions of the VTA
As above, a total amount of 8 mg of 6-OHDA (4 mg/ml,
dissolved in 0.02% ascorbic acid) was unilaterally injected into the
right VTA (A/P 25.3; L/M 20.9; D/V 28.3) at a flow rate of
0.5 ml/min using a 10 ml Hamilton microsyringe run by a micro-
dialysis pump (QSI, Stoetling, Wood Dale, Il, USA). For an
illustration of the injection site and main projection areas
[14;15;16], please refer to Figure 1A–C.
Table 2. Dopamine levels after 6-OHDA-lesions and noradrenaline levels after DSP-4 lesions.
Intact side or control animal Lesioned side/animal
6-OHDA lesion (lateral SN) Dopamine (ng/mg)
n N
PFC 5 0.2660.04 5 0.3060.08 (116.9%)
Striatum 5 26.965.62 5 15.162.91 (56.1%)
NAcc 5 5.2861.10 5 4.5860.55 (86.7%)
Hippocampus 5 0.2160.08 5 0.2660.08 (123.8%)
6-OHDA lesion (VTA) Dopamine (ng/mg)
n N
PFC 5 0.2960.09 5 0.1160.05 (38.2%)
Striatum 5 23.965.56 5 1.9961.53 (8.3%)**
NAcc 5 6.361.88 3 0.6860.28 (10.7%)*
Hippocampus 5 0.1160.03 5 0.1160.05 (93.1%)
DSP-4 lesion Noradrenaline (ng/mg)
n N
PFC 5 0.68260.059 4 0.02960.006 (4.2%)***
Striatum 5 0.24960.088 4 0.04360.004 (17.5%)*
Hypothalamus 5 464260.307 4 247760.347 (53.4%)**
Hippocampus 5 0.58260.045 4 0.06360.06 (30.4%)***
Cerebellum 5 0.249560.088 4 0.00960.004 (3.8%)*
The results (mean6sem) are expressed as absolute values (ng/mg) and as percentage (in parenthesis) of the intact side (6-OHDA) and control animals (DSP-4) set as 100.
Significant differences from intact or controls values:
*p,0.05;
**p,0.01;
***p,0.001. Key: PFC, prefrontal cortex; NAcc, nucleus accumbens; SN, substantia nigra; VTA, ventral tegmental area.
doi:10.1371/journal.pone.0061392.t002
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DSP-4 Lesions of the Locus Coeruleus
Rats received intraperitoneal injections of N-(2-chloroethyl)-N-
bromobenzylamine hydrochloride (DSP-4, 50 mg/kg). The dose
of DSP-4 was weighed separately for each animal, dissolved in
saline and injected immediately. Control animals received saline
injections. For an illustration of the main projection areas of the
locus coeruleus [17;18], please refer to Figure 1D.
Tissue Collection
Two separate experiments were made using either dopaminer-
gic 6-OHDA or noradrenergic DSP-4 lesions. At the end of both
the experiments, the rats were decapitated, the brains were
immediately removed, and the samples dissected slightly differ-
ently in the two experiments. In the 6-OHDA studies, the tissue
samples were collected separately from both brain sides and the
unlesioned side was used as a control. In the DSP-4 studies,
a group of unlesioned rats was used as a control, and the tissue
samples from both sides of the brain were combined. Samples of
specific brain areas were dissected based on visual inspection,
landmarks and coordinates measured from bregma. In the 6-
OHDA experiments, the samples from the nucleus accumbens
(punching) and dorsal striatum were dissected separately in order
to precisely dissociate these areas to compare the effects of the
lateral substantia nigra and VTA lesions. In the DSP-4 experi-
ments, these striatal areas were not separated. After dissection, the
tissue samples were weighed and placed in plastic microfuge tubes,
frozen on dry ice and stored at 280uC until further assayed.
In the 6-OHDA experiments, the brain samples were collected
in the following order: the PFC, nucleus accumbens, dorsal
striatum and hippocampus. The brains were placed on the ice-cold
glass plate. The PFC was separated from the front of the brain
with a razor blade and coronally sectioned as follows: the ventral
area to the rhinal fissure was discarded and vertical cuts at 1 mm
from the midline were made on both sides. A three mm thick slice
containing both nucleus accumbens and dorsal striatum was
separated frontally from the brain at optic chiasma (20.3 mm).
The nucleus accumbens was punched out from the slice (a coronal
punch diameter was 2 mm). The dorsal striatum was squeezed off
based on its visual looks with forceps frontally of the nucleus
accumbens. Both hippocampal areas were finally rolled out and
peeled off from the rest of the brain using forceps.
In the DSP-4 experiments, the samples were collected in the
following order: the PFC, hypothalamus, whole striatum, hippo-
campus and cerebellum. The brains were dissected on the ice-cold
glass plate. Both sides of the PFC were cut with a razor blade as
described above. A coronal cut of the brain was made at optic
chiasma (20.3 mm). The hypothalamus was dissected by cutting
its borders and pinched out. Both striata were removed frontally
from the cut based on its visual looks by forceps as one sample
containing both dorsal parts and nucleus accumbens. The
hippocampus was peeled off from both sides and the cerebellum
was removed with forceps.
Monoamine Analysis
Brain levels of dopamine, noradrenaline and 5-hydroxytrypta-
mine (5-HT) were measured using high-performance liquid
chromatography (HPLC) with electrochemical detection as de-
scribed previously [19]. Briefly, brain samples were dissected and
placed into eppendorf tubes and kept on dry ice until stored at
280uC. The samples were homogenized in 0.5 ml of homogeni-
zation solution consisting of 6 parts of 0.2 M HClO4 and 1 part of
antioxidant solution containing oxalic acid in combination with
acetic acid and L–cysteine. The homogenates were centrifuged at
20 800 g for 35 min at 4uC. Supernatants were removed to 9.5 ml
VivaspinH filter concentrators (10 000 MWCO PES; Vivascience
AG, Hannover, Germany) and centrifuged at 8600 g at 4uC for
35 min. The column (SpherisorbH ODS2 3 mm, 4.66100 mm2;
Waters, Milford, MA, USA) was kept at 50uC with a column
heater (Croco-Cil, Bordeaux, France). The mobile phase consisted
of 0.1 M NaH2PO4 buffer, 350 mg/l of octane sulfonic acid,
methanol (3–6.5%), and 450 mg/l EDTA. The pH of the mobile
phase was set to 2.7 using H3PO4. The pump (ESA Model
582Solvent Delivery Module; ESA, Chelmsford, MA, USA) was
equipped with a pulse dampener (SSI LP-21, Scientific Systems,
State College, PA, USA) and the flow rate was 1 ml/min. Sixty ml
of the filtrate were injected into the chromatographic system with
a CMA/200 autoinjector (CMA, Stockholm, Sweden).
Monoamines were detected using ESAH CoulArray Electrode
Array Detector (voltages gradually increased from +100 to
+300 mV), and chromatograms were processed and concentra-
tions calculated using CoulArrayH for windows softwareH (ESA,
Chelmsford, MA, USA). CoulArray detector has several coulo-
metric cells in series. Each cell has unique voltage and the analytes
are analysed by corresponding dominant cell according to
Figure 2. Successful dopaminergic lesions do not cause changes in the COMT protein levels. A normalized optical density (OD) analysis of
(A) tyrosine hydroxylase (TH) or (B) COMT positive neurons in the substantia nigra (SN) and striatum (Stri) after a unilateral 6-OHDA (8 mg) lesion of
the SN, and TH and COMT positive neurons in the prefrontal cortex (PFC) after 6-OHDA lesion of the VTA. At least 3 separate stainings were done, and
mean 6 SEM are shown. Significant decrease in TH OD was seen in all areas analyzed but none in COMT OD. ***, P,0.001; **, P,0.01 vs. control side
(Student t-test).
doi:10.1371/journal.pone.0061392.g002
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calibration sample response. These voltages are suitable for
analysis of all reducable/oxidable monoamines.
When analysing either the 6-OHDA or DSP-4 lesioned tissues,
we have used HPLC conditions optimized for dopamine or
noradrenaline analysis, respectively. In case of dopamine run,
noradrenaline comes very rapidly in the solvent front, whereas in
the case of noradrenaline run the retention time of dopamine slows
down. Here, for practical reasons, noradrenaline was not analysed
in dopamine runs.
The monoamine values are expressed as nanograms per
milligram (ng/mg) wet weight of tissue. Dopamine levels in
terminal areas were measured after 6-OHDA treatments and
noradrenaline and 5-HT levels after DSP-4 treatment. The
detection limit of all these monoamine (i.e. dopamine, noradren-
aline and 5-HT) analytes was 0.1 ng. The signal to noise -ratio was
5. The analytical variation within the day was 2.2% for dopamine,
12.1% for noradrenaline and 3.4% for 5-HT (n= 3 duplicate
measurements).
COMT Protein Expression
COMT protein amounts were measured using standard
Western Blotting procedures as described previously [20;21]. In
short, the tissue samples were homogenized using a sonicator
(Rinco Ultrasonics sonicator, Arbon, Switzerland) in 20 volumes of
homogenization buffer (10 mM Na2HPO4, pH 7.4, containing
0.5 mM dithiothreitol). The homogenates were centrifuged at
890 g at +4uC for 10 min and the supernatants were collected.
The samples were then diluted with Laemmli buffer so that 20 mg
of total protein was loaded and electrophoresis was performed in
a 12% SDS-polyacrylamide gel. Subsequently, samples were
blotted onto ProtranH nitrocellulose transfer membrane (Schlei-
cher & Schuell Bioscience GmbH, Dassel, Germany). After
blocking nonspecific binding, the membranes were incubated
with mouse anti-COMT monoclonal antibody overnight at +4uC
(1:5000; BD Bioscience Pharmingen, San Diego, CA, USA).
Following this, the membranes were processed with goat anti-
mouse secondary antibody (1:2000; R&D Systems, Minneapolis,
MN, USA) conjugated with horseradish peroxidase. Blots were
visualized using chemiluminescent substrate (Thermo scientific,
Rockford, IL, USA) and detected and quantified using GeneG-
nome chemiluminescent detector and corresponding software
(SynGene, Synoptics LTD, UK). Beta actin was used as a loading
control. S-COMT and MB-COMT were seen as separate bands
and the densities of these bands were quantified.
COMT Activity Analysis
The COMT enzyme activity assay was assessed using HPLC
with electrochemical detection as described earlier [20;21] using
the same homogenate as with Western Blot studies. In brief, the
enzyme homogenate preparation was incubated at +37uC in
100 mM phosphate buffer (pH 7.4) containing 5 mM MgCl2,
200 mM S-adenosyl-L-methionine and 500 mM 3,4-dihydroxy-
benzoic acid. A high-performance liquid chromatographic
(HPLC) system with electrochemical detection was used to analyze
Figure 3. A–C. Selective dopaminergic lesions do not affect
COMT protein expression and activity. 6-OHDA (8 mg) was
unilaterally infused either to the lateral substantia nigra (SN) or ventral
tegmental area (VTA). COMT protein expressions were unaltered in any
of the dopaminergic projection areas in the SN (A) or VTA (B) in
agreement with unchanged enzyme activity (C). In dopaminergic lesion
studies, animals received unilateral infusions of 6-OHDA and therefore
the results are expressed as percentage of the intact side set as 100.
Mean 6 SEM, n = 4 in the SN control group, otherwise n = 5.
doi:10.1371/journal.pone.0061392.g003
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the reaction products, vanillic acid and isovanillic acid. The system
consisted of a sample autoinjector (Jasco AS-2057, Tokyo, Japan),
a pump (Merck Hitachi LaChrom L-7100, Tokyo, Japan), an RP-
18 column (3 mm, 4.66150 mm; Waters Spherisorb, Milford,
MA, USA), a coulometric detector (ESA Coulochem model 5100A
detector and a model 5014B cell; ESA Inc., Chelmsford, MA,
USA; E1 detector potential was 20.32 V and that of E2 analytical
detector +0.5 V) and an integrator (Shimadzu C-R5A; Shimadzu
Corporation, Kyoto, Japan). The mobile phase consisted of 0.1 M
Na2HPO4 (pH 3.3), 0.15 mM EDTA and 25% methanol; the
flow-rate was 0.8 ml/min.
The protein concentrations of the samples were determined
based on the bicinchoninic acid method using Pierce protein assay
kit (Pierce Biotechnology, Rockford, IL, USA). COMT activity is
expressed as picomoles vanillic acid formed in one min per mg of
protein in the sample.
Double-label Immunofluorescence
COMT, tyrosine hydroxylase (TH), choline acetyltransferase
(ChAT) and glutamic acid decarboxylase (GAD)-immunofluor-
escences were revealed by modifying the protocol described in
Myo¨ha¨nen et al. [7]. Briefly, rats were deeply anesthetized using
pentobarbital (Orion Pharma, Espoo, Finland) and then perfused
using saline followed by 4% paraformaldehyde in PBS, pH 7.4.
After perfusion, the rats were decapitated, brains were removed
and stored at 270uC until sectioning into 40 mm free-floating
cryosections with a microtome (Leica M3050, Leica Microsystems
Inc., Wetzlar, Germany). Free-floating sections were first washed
with PBS, boiled for 30 min at +80uC in citrate buffer (pH 6.0) for
antigen retrieval and then washed 3615 min in PBS. After that,
the sections were incubated in blocking solution (10% normal goat
serum in PBS containing 0.5% Triton X-100; Vector laboratories,
Burlingame, CA, USA) for 30 min followed by an overnight
incubation with each primary antibody (see details of primary
antibodies in Table 1). After washing with PBS the sections were
incubated with secondary antibody (dilutions 1:500, Fluorescein
conjugated goat anti-rabbit IgG, Product # 31635, Pierce
Biotechnology) for 2 h. Double-immunofluorescence with
COMT-antibody followed after PBS washes. The procedure was
similar to the first staining, and COMT-immunocomplexes were
detected using rabbit anti-mouse with Texas Red conjugate
(dilution 1:500, Product #31610, Pierce Biotechnology) as
a secondary antibody. Vectashield with DAPI (Vector Laborato-
ries) was used as a mounting medium to demonstrate the nuclei of
the cells. Control stainings for immunohistochemistry were carried
out with the omission of the primary antibodies. For all
immunostainings, three separate stainings from different animals
were done.
Fluorescent double-labeled sections were analyzed and photo-
graphed using Leica TCS SP2 AOBS (Leica Microsystems)
equipped with an argon-He/Ne laser mounted on an inverted
Leica DM IRE2 microscope (Leica Microsystems). After capturing
the images with an imaging device, confocal double-labeled
immunofluorescence micrographs were merged using Adobe
Photoshop CS2 software (version 9.0, Adobe Systems Incorporat-
ed). Only minor corrections to brightness and contrast were made.
Figure 4. A–X. COMT protein neither colocalized with tyrosine hydroxylase (TH) positive neurons nor decreased after destruction
of dopamine neurons. The effect of dopaminergic lesion on the COMT immunoreactivity. The 6-OHDA lesion of the substantia nigra (SN) and
ventral tegmental area (VTA) were made as described and COMT immunoreactivity analysed in the projection areas. In the intact SN, COMT (red color)
was not colocalized with dopaminergic neurons (tyrosine hydroxylase, TH; green color; A–D), and lesion in the SN did not affect COMT
immunoreactivity (E–H) although TH-immunoreactivity disappeared (E). The situation was similar in the striatum (Stri; I–L versus M–P). Moreover, in
the intact prefrontal cortex (PFC), the projection area of the VTA, COMT did not colocalize with dopaminergic nerves (Q–T). Moreover, the lesion in
the VTA did not effect on COMT on the PFC (U–W). Nuclei are visualized by DAPI (blue color). Scale bars are 10 mm in all pictures. Three separate
stainings were made and representative examples are shown. Quantification of ODs was done in Fig.2.
doi:10.1371/journal.pone.0061392.g004
Figure 5. A–B. Selective noradrenergic lesions do not change COMT protein expression and activity. COMT protein expression (A) and
activity (B) were unaltered in any of the noradrenergic projection areas. To destroy noradrenergic neurons, animals were injected i.p. with DSP-4
(50 mg/kg) and control animals received i.p. injections of saline (vehicle). The results are expressed as percentage of the control animals set as 100.
Mean 6 SEM, n= 5.
doi:10.1371/journal.pone.0061392.g005
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Figure 6. A–G. Lack of the effect of noradrenergic lesion on COMT immunoreactivity. DSP-4 lesion of noradrenergic neurons did not affect
COMT-immunoreactivity (red color) in noradrenergic projection areas, the prefrontal cortex (PFC; A–B), striatum (Stri; C–D) and hippocampus CA1 (Hc
CA1; E–F). Three separate stainings were done, and the COMT optical densities are quantified in Fig. 6G. Nuclei are visualized by DAPI (blue color).
Scale bars are 10 mm in all pictures.
doi:10.1371/journal.pone.0061392.g006
Dopaminergic and Noradrenergic Innervation of COMT
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Figure 7. A–T. COMT protein is colocalized with a GABAergic (glutamate decarboxylase, GAD65/67; green) but less or none with
a cholinergic marker (choline acetyltransferase, ChAT; green). In the striatum (Stri), COMT (red) was found to be colocalized with GABAergic
neurons and fibres (A–D; white arrows and yellow color depicting colocalization), while no colocalization with cholinergic nerves was seen (E–H).
Moreover, COMT was not colocalized with cholinergic neurons in the medial septum (MS; I–L). In the cortex, COMT was also colocalized with
Dopaminergic and Noradrenergic Innervation of COMT
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Semiquantitative Analysis of COMT and TH Staining after
Lesions
After capturing the fluorescent photomicrographs of the
immunostained sections, the images were analyzed using Bio-
Rad QuantityOne 4.5.1 software (Bio-Rad Laboratories, Hercu-
les, CA, USA) as described earlier [22]. In optical density (OD)
analysis, representative area of brain structure was delineated with
the box tool of the software. The background value of each area
(unstained zone in the area, e.g. cell nucleus) was subtracted from
raw data values of the same area. The average of intact brain
structure OD values was set as 100% and corresponding lesioned
brain structure was compared to that value. Altogether 2–3
sections/animal from 3 different animals were analyzed.
Statistics
All values are expressed as means 6 SEM. Statistical analyses
for significant differences was performed with unpaired t-test using
GraphPad Prism 5.0 program (GraphPad Software, Inc., San
Diego, CA, USA). The criterion for statistical significance was
p,0.05.
Results
Dopamine Levels in the Projection Areas of the Lateral
SN after 6-OHDA Lesion
Dopamine levels were decreased (p= 0.098; t = 1.870) to 56% in
the dorsal striatum after selective lesion of the lateral SN (Table 2).
In comparison, dopamine levels in other brain areas, e.g. the PFC
and hippocampus (not shown) were not affected. Decreased
dopamine levels in the dorsal striatum, the projection area of the
lateral SN, indicate moderate but selective lesions of presynaptic
nigrostriatal dopaminergic neurons. In a semiquantitative analysis,
TH expression was significantly reduced both in the SN (to 7%)
and striatum (to 27%; Fig. 2A).
Dopamine Levels in the Projection Areas of the VTA after
6-OHDA Lesion
Lesioning of the VTA with 6-OHDA resulted in decreased
dopamine levels in the projection areas (Table 2), namely to about
38% in the PFC (p= 0.117; t = 1.176), to 8% in the dorsal striatum
(p,0.01), and to 11% (p,0.05) in the nucleus accumbens. In the
hippocampus, dopamine levels remained unaffected (not shown).
In a semiquantitative analysis, TH expression was significantly
reduced in the PFC (to 65%; Fig. 2A).
Monoamine Levels in the Projection Areas of the Locus
Coeruleus after DSP-4 Lesion
The locus coeruleus sends many projection neurons throughout
the entire brain. We found decreased noradrenaline levels in the
PFC (to 4%), striatum (to 18%), hypothalamus (to 53%)
hippocampus (to 11%), and cerebellum (to 4%), indicating
a successful destruction of noradrenergic neurons by DSP-4
(Table 2). 5-HT levels were in the control/lesioned animals as
follow: 0.4260.03/0.3260.04 (PFC), 0.3160.024/0.2460.031
(striatum), 0.7860.064/0.5260.11 (hypothalamus), 0.2760.059/
0.1260.014 (hippocampus) and 0.03960.003/0.03860.003 (cer-
ebellum), respectively, showing a maximum decrease to 44% in
the hippocampus (p= 0.228; t = 2.078). The unchanged dopamine
levels (not shown) in any measured brain areas (e.g. 15.7 ng/mg
and 14.8 ng/mg in the striatum of control (n = 5) and DSP-4
(n= 4) rats, respectively) from the DSP-4 treated rats support the
selectivity of noradrenergic lesions.
Expression of COMT and TH Proteins, and COMT Activity
after 6-OHDA Infusion to the Lateral SN
Despite successful lesioning of dopaminergic neurons projecting
from the lateral SN to the dorsal striatum, expression of both
COMT protein isoforms (Fig. 3A) and COMT activity (Fig. 3C)
remained unchanged. These results indicate that COMT is not
located in dopaminergic nigrostriatal projection neurons. More-
over, no significant changes in COMT-immunoreactivity was seen
in the SN and striatum (Figs. 2B and 4A–P), although TH positive
neurons disappeared from both brain regions after nigral lesions as
a further proof of the dopaminergic damage (Fig. 2A).
Expression of COMT and TH Proteins, and COMT Activity
after 6-OHDA Infusion to the VTA
When dopaminergic neurons originating in the VTA and
projecting to the nucleus accumbens or dorsal striatum were
selectively destroyed by infusing 6-OHDA to the VTA, expression
of both COMT protein isoforms (Fig. 3B) and COMT activity
(Fig. 3C; e.g., for NAcc, p = 0.104, t = 1.836 ) remained unaltered,
suggesting that COMT is not present in these neurons. This was
verified by immunofluorescence staining, where no changes in the
COMT-immunoreactivity was seen in the PFC (Figs. 2B and 4U–
W), a projection area of the VTA although TH expression was
strongly reduced supporting a significant dopaminergic damage
(Figs. 2A and 4Q–X).
COMT Activity and Expression of COMT and TH Proteins
after DSP-4 Lesion
COMT protein expression (Fig. 5A) and COMT activity
(Fig. 5B) were not affected by DSP-4 treatment. Furthermore,
COMT immunoreactivity was not changed in the PFC, striatum
or hippocampus (Fig. 6A–F). This observation suggests that
COMT is not present in noradrenergic neurons originating from
the locus coeruleus.
Colocalization of COMT with GABAergic and Cholinergic
Markers
We also examined the colocalization of COMT with a GA-
BAergic marker (GAD65/67) and a cholinergic marker (ChAT) in
the striatum and cerebral cortex (primary motor cortex) in the
DSP study. Moreover, a colocalization of COMT with ChAT was
studied in the medial septum, one origin of cholinergic cell bodies
[23]. COMT was seen colocalized with GABAergic neurons and
nerve fibers in the striatum and cortex (Fig. 7A–D, M–P).
Colocalization of COMT with cholinergic nerves was seen neither
in the striatum (Fig. 7E–H) nor in cholinergic cell bodies in the
medial septum (Fig. 7I–L). However, a weak colocalisation of
COMT with cholinergic nerves in the cortex was observed (Fig. 7
Q–T).
Discussion
The aim of this study was 1) to site-selectively destroy
dopaminergic cell bodies located either in the lateral SN or
VTA utilizing 6-OHDA, and 2) to demolish a major part of
GABAergic interneurons (M–P; white arrows, yellow color) and a weak colocalization with some cholinergic nerves was seen (Q–T). Nuclei are
visualized by DAPI (blue color). Scale bars are 10 mm in all pictures. Three separate stainings were done and representative examples are shown.
doi:10.1371/journal.pone.0061392.g007
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noradrenergic neurons via DSP-4, and 3) to subsequently measure
potential changes in COMT activity and protein expression in
several projection areas of the destroyed neurons. In addition, we
also wanted to address the possible colocalization of COMT with
GABAergic and cholinergic neurons in the respective projection
areas using double-label immunofluorescence.
The presence of COMT in the nigrostriatal dopaminergic
neurons has been previously investigated by Kaakkola and
colleagues [2]. The authors lesioned the medial forebrain bundle
which contains dopaminergic neurons originating from the VTA
and SN and report unaltered COMT protein expression and
activity in the striatum, a main target area. However, due to the
extensive lesion the authors were unable to distinguish between the
SN and VTA dopaminergic neurons. Our study was designed to
selectively destroy either dopaminergic neurons originating from
the SN or VTA, or noradrenergic neurons originating from the
locus coeruleus, and to give a more thorough and detailed analysis
of COMT enzyme in dopaminergic and noradrenergic projection
areas. Because the SN and VTA are anatomically close to each
other, we first confirmed that we are able to target either one of
the two areas separately without damaging the adjacent area. It
was confirmed that the diffusion patterns of methylene blue do not
overlap in these two sites (Fig. 1B).
Successful lesioning of dopaminergic neurons originating from
the lateral SN was confirmed by decreased dopamine levels in the
dorsal striatum (to 56% compared to the intact side), the main
projection area of the lateral SN. Moreover, in immunofluores-
cence, a disappearance of TH-positive dopaminergic neurons in
the SN and striatum was observed. In comparison, dopamine
levels remained unaltered in the PFC and hippocampus. The
rather small decrease in the striatal dopamine is likely due to the
non-optimum position of the lesion site. We purposely targeted
only the lateral part of the SN to avoid spill-over of 6-OHDA to
the VTA. Nevertheless, slightly decreased dopamine levels in the
nucleus accumbens (to 87% compared to the intact side) suggest
that some of the 6-OHDA may have spread to the medial part of
the SN, since this area connects to the nucleus accumbens. Despite
successful lesioning, the absence of changes in COMT protein and
activity indicates that COMT is not present in dopaminergic
neurons of the nigrostriatal tract. This was further supported by
a double-label immunofluorescence, where no colocalization
between COMT and TH-positive dopaminergic neurons was
seen in the SN and striatum.
Decreased dopamine levels in the PFC (to 38% compared to the
intact side), dorsal striatum (to 8% compared to the intact side) and
nucleus accumbens (to 11% compared to the intact side) indicate
an effective loss of dopaminergic neurons originating from the
VTA. However, COMT protein and activity did not change.
Collectively, these results strongly suggest that COMT is not
localized in dopaminergic connections of the VTA.
Studies utilizing kainic acid to selectively destroy GABAergic
and cholinergic neuronal cell bodies in the striatum report
decreased MB-COMT activity, indicating the presence of MB-
COMT in these postsynaptic terminals [4]. Furthermore, the
authors described an increase in S-COMT activity, suggesting that
S-COMT is present in glial cells [4]. An administration of 6-
OHDA directly to the striatum causes a significant inflammatory
response in the striatum and SN, and an increase in microglial
response [24]. Several studies report similar findings after local
insults [6;25], and that the increase in S-COMT is more
pronounced than that of MB-COMT [25]. However, after the
nigral injections of 6-OHDA to destroy nigrostriatal dopamine
nerves, the glial response in the striatum has been scanty and
absent within three weeks [26;27]. Moreover, COMT-immuno-
reactivity is even reduced in astroglial cells following insults [26].
Collectively, we assume that changes in the neuronal COMT
activity and expression in the striatum, measured at 3 weeks post
lesions of the SN, are not notably masked by a transient increase of
microglial COMT in the striatum.
While the presence of COMT in presynaptic dopaminergic
neurons has been extensively studied, only few reports address the
existence of COMT in presynaptic terminals of noradrenergic
neurons. Several studies propose that COMT is present in
peripheral noradrenergic neurons [28;29;30]. However, the
presence of COMT in presynaptic noradrenergic neurons in the
brain is still uncertain [28;31]. Accordingly, in our study, although
noradrenaline levels were strongly reduced in all analyzed
projection areas of the locus coeruleus indicating effective lesions,
we observed no changes in COMT protein expression or activity.
These results indicate the absence of COMT from presynaptic
noradrenergic neurons originating from the locus coeruleus. A
selectivity of noradrenergic lesions was estimated by the measure-
ment of 5-HT levels in the projection areas of the locus coereleus.
After the DSP-4 lesions, the levels of noradrenaline were decreased
significantly with minor decreases in 5-HT levels. Therefore, these
results indicate that the obtained selectivity although not complete
was sufficient for the present study.
Furthermore, when using a double-label immunofluorescence to
examine the localization of COMT in GABAergic and cholinergic
neurons in their projection areas [32;23], we detected the COMT
protein especially in GABAergic neurons of the striatum and
cortex. However, no convincing colocalization with a cholinergic
marker, ChAT, was seen in cholinergic nerves or cell bodies of the
striatum or septum. Only in some cortical areas a weak
colocalization of COMT and cholinergic staining was seen, the
latter in the nerve endings. These results show that, in addition to
glial cells, COMT is localized in GABAergic neurons but evidently
usually not in cholinergic neurons. Although we did not mark
glutamatergic cells, we have shown before that COMT resides also
in several brain areas that have glutamate as a major transmitter
[7]. Therefore, it is probable that even the glutamatergic neurons
contain COMT.
In conclusion, our results suggest that COMT is not signifi-
cantly present in terminals of presynaptic dopaminergic and
noradrenergic neurons. Instead, COMT is abundantly found in
postsynaptic GABAergic neurons in the striatum and cortex.
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